Lower motor neuron involvement in ALS assessed by motor unit number index (MUNIX): Long-term changes and

Davood Fathi1, Bahram Mohammadi2, Reinhard Dengler3

  • 1Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; International Neuroscience Institute, Hannover, Germany.

Abstract

Insights

Motor Unit Number Index (MUNIX) shows consistent reproducibility in amyotrophic lateral sclerosis (ALS) patients. This technique reliably tracks motor neuron loss, aiding clinical management and treatment trials for ALS progression.

Area of Science:

  • Neurology
  • Neurophysiology

Background:

  • Motor Unit Number Estimation (MUNE) techniques, including Motor Unit Number Index (MUNIX), are vital for quantifying motor neuron loss in amyotrophic lateral sclerosis (ALS).
  • Assessing the reproducibility of MUNIX is crucial for its reliable application in tracking disease progression.

Purpose of the Study:

  • To investigate the consistency and reproducibility of MUNIX measurements in ALS patients over time.
  • To evaluate MUNIX's potential for monitoring disease progression in clinical settings and therapeutic trials.

Main Methods:

  • MUNIX was measured bilaterally in the abductor pollicis brevis and tibialis anterior muscles of 30 ALS patients at two time points.
  • Measurements were also taken in healthy controls.
  • Intra-rater reproducibility was assessed using interclass correlation coefficient (ICC), correlation coefficient analysis (CCA), and coefficient of variation (CV).

Main Results:

  • A significant correlation was observed between the first and second MUNIX measurements in all tested muscles (r⩾0.891, p<0.01).
  • High statistical reproducibility of MUNIX was confirmed in all four measured muscles at follow-up (ICC⩾0.946, p<0.01).
  • The coefficient of variation (CV) for MUNIX at follow-up ranged from 13.90% to 32.95%.

Conclusions:

  • The study demonstrates good consistency and reproducibility of MUNIX measurements throughout the course of ALS.
  • MUNIX is a reliable tool for tracking disease progression in ALS patients.
  • The findings support the use of MUNIX in routine clinical practice and for monitoring outcomes in ALS treatment trials.